Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

It’s only 2012, but Russia’s Pharma 2020 program hit new highs last month with novel deals from Abbott, J&J, Merck and Pfizer.

You may also be interested in...



To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano

The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.

Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local

Russia Premier Vladimir Putin has said he wants multinational pharmaceutical companies to manufacture drugs in Russia and support development of the local industry as part of a $4 billion government initiative to reform the Russia healthcare market by 2020. So perhaps it is not too surprising that both Novartis AG and AstraZeneca PLC chose to re-emphasize their commitments to Russia by each issuing press releases June 16 to coincide with the kickoff of the St. Petersburg International Economic Forum

Roche Extends Russian Presence, Inks Second Agreement With ChemRar

Heeding a government call to support local innovation, Swiss drug maker Roche has stepped up efforts in the fast-growing Russia pharma market, announcing a licensing agreement May 24 with TeaRx Ltd. that will provide the Moscow-based start up with development and commercialization rights for an experimental anti-thrombotic candidate in Russia and 12 other countries

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC081567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel